Clinical Neurology

Research activity at neurology is strongly patient-oriented. Scientific questions arise from daily clinical practice and are solved by means of clinical/interventional studies and translational studies using biobank material.

Research fields include common neurological diseases such as epilepsy, movement disorders, acute stroke and multiple sclerosis but also more rare disorders like neurogenetic disorders and low-grade gliomas.

Clinical and interventional studies

- In collaboration with the PET Centre, the value of 11C-L-DOPA and 18F-FDG-PET is studied for differential diagnosis of Parkinson’s disease, 11C-flumazenil as a tracer for focal epilepsy and 11C-methionine in low-grade gliomas.

- Advanced neuroimaging techniques are evaluated, in collaboration with the Department of Neuroradiology, for diagnosis and follow-up of normal pressure hydrocephalus (NPH), multiple sclerosis (MS), neurogenetic disorders, focal epilepsy, brain tumors, stroke and movement disorders.

- Neurology in Uppsala was first in Sweden to use botulinum toxin, a drug that in addition to focal dystonia is used also for spasticity after stroke and hyperhidrosis, and was first worldwide to use intestinal levodopa/carbidopa gel infusion in advanced Parkinson’s disease. A multicenter trial has been initiated to compare the efficacy of intestinal levodopa/carbidopa gel infusion versus of deep brain stimulation.

- Since 2004, around 20 patients with aggressive MS have beeen treated with haematopoietic stem cell transplantation (HSCT) with a strongly favourable effect on disease activity. A multi-center prospective trial comparingHSCTwith natalizumab in these patients is ongoing.

- Epidemiological studies on the efficiency, safety, and sociodemographic distribution among recently adopted treatment options in epilepsy are performed.

Clinical translational studies

Tanslational projects include pathogenetic studies of hereditary neuromuscular disorders and white matter diseases, immunological studies of MS, pharmacokinetic-pharmacodynamic modelling in Parkinson’s disease, identification of prognostic and predictive biomarkers in tumor tissues of adult low-grade gliomas, and in serum and CSF of patients with ALS and Parkinson´s disease.